{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:18:57Z","timestamp":1788347937600,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Antibodies to hepatitis B core antigen (anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c) testing were added to hepatitis surface antigen (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg) screening in Germany in 2006 to prevent hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) transmissions by chronically infected donors. We\u00a0report the results of a national surveillance of anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c\u2010reactive and <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg\u2010negative donations and assess the resulting gain in blood safety and the donor loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Donations were tested for anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c, and if reactive, by sensitive individual donation nucleic acid testing (<jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>) and for antibodies to <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg (anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s). Data from the national anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c surveillance from 2006 to 2015 determined the proportion of anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c\u2010reactive donations stratified for donor type, sex, anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s concentration and <jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>\u2010positivity. Donor loss due to anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c\u2010reactive results was quantified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 31\u00a0562\u00a0556 donations screened, 70\u00a0671 were anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c reactive but <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>sAg negative (0.22%). The proportion of repeat donors with these test results decreased significantly from 0.25% in 2007 to 0.08% in 2015. In the entire study period, 82 <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>\u2010positive donations were identified. Of these, 47 donations were only identified by <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>. A total of 54\u00a0203 anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c\u2010reactive units were discarded either due to possible infectiousness (<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content> positive or anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s concentration &lt;100\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/l) or because no further testing was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c screening has improved blood safety in Germany. <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>\u2010positive donations were identified after <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content> was triggered by the initial reactive anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c result. The observed loss of donations was sustainable for maintaining an adequate blood supply in Germany.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12781","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T10:17:41Z","timestamp":1554891461000},"page":"459-466","source":"Crossref","is-referenced-by-count":14,"title":["Anti\u2010<scp>HB<\/scp>c screening \u2013 is it worth the effort? Results of a 10\u2010year surveillance programme covering more than 30 million donations in Germany"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-4956","authenticated-orcid":false,"given":"Claudia","family":"Houareau","sequence":"first","affiliation":[{"name":"Robert Koch Institute Berlin Germany"},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Offergeld","sequence":"additional","affiliation":[{"name":"Robert Koch Institute Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-008-0612-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-010-1152-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-012-1516-1"},{"key":"e_1_2_8_5_1","unstructured":"German Blood Donor Surveillance:HIV\u2010 HCV\u2010 HBV\u2010 and Syphilis Infections of Blood and Plasma Donors 2011\u20102015.https:\/\/www.rki.de\/DE\/Content\/Infekt\/Blut\/Transfusionsmedizin\/Infektionsdaten\/infektionsdaten_node.html(Last accessed 11 December 2018)."},{"key":"e_1_2_8_6_1","unstructured":"Paul\u2010Ehrlich\u2010Institut.Abwehr von Arzneimittelrisiken. Testung auf Antik\u00f6rper gegen Hepatitis\u2010B\u2010Core\u2010Antigen (anti\u2010HBc) im Blutspendewesen(vom 08. Mai 2006).https:\/\/www.pei.de\/SharedDocs\/bekanntmachungen\/2006\/banz-109-13-06-2006-s4370.html?nn=3250044(Last accessed 11 December 2018)."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21499"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00912.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20963"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-005-1067-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12962"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.05.009"},{"key":"e_1_2_8_13_1","unstructured":"Paul\u2010Ehrlich\u2010Institut.:Abwehr von Arzneimittelrisiken. Testung auf Antik\u00f6rper gegen Hepatitis\u2010B\u2010Core\u2010Antigen (Anti\u2010HBc) im Blutspendewesen.2014: Bundesanzeiger"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-008-0682-7"},{"key":"e_1_2_8_15_1","first-page":"1752","article-title":"Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz) vom 1.Juli 1998","volume":"42","year":"1998","journal-title":"Bundesgesetzblatt"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01635.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03283.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-013-1673-x"},{"key":"e_1_2_8_19_1","unstructured":"Einf\u00fchrung der HBV\u2010Impfung. Bundesgesundheitsblatt.1996:1"},{"key":"e_1_2_8_20_1","first-page":"845","article-title":"Vaccination coverage in German adults","volume":"56","author":"Poethko\u2010M\u00fcller C","year":"2013","journal-title":"Bundesgesundheitsbl"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(06)80007-7"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01701.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00345-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0958-7578.2004.0486.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01245.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2017.06.014"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12198"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12096"},{"key":"e_1_2_8_29_1","first-page":"146","article-title":"Transmission of occult HBV infection by ID\u2010NAT screened blood","volume":"107","author":"Vermeulen M","year":"2014","journal-title":"Vox Sang"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.016"},{"key":"e_1_2_8_31_1","first-page":"91","article-title":"Transfusion\u2010transmission of hepatitis B virus (HBV) from a NAT\u2010negative occult hepatitis B virus carrier","volume":"101","author":"Hanada D","year":"2011","journal-title":"Vox Sang"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03031.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00577.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01292.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01903.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01973.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000477942"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.12781","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:06:42Z","timestamp":1693822002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/vox.12781"],"URL":"https:\/\/doi.org\/10.1111\/vox.12781","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]}}}